GlobeNewsWire
16 Nov 2026, 07:00 UTC · 18h ago
Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses
Impact · against what's priced in
Oculis gains a potential catalyst by expanding its pipeline into acute MS relapses via FDA IND clearance. This increases the long-term total addressable market beyond its current focus on optic neuritis.
- OCUL+0.60
No priced-in read yet





